Skip to main
  1. Stocks
  2. MapLight Therapeutics Inc
  3. Forecast
MPLT

MPLT Stock Forecast & Price Target

MPLT Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 64%
Buy 18%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

MapLight Therapeutics is attractive because its ML-007C-MA program targets two large, underserved CNS markets—schizophrenia and Alzheimer’s disease psychosis—with a differentiated muscarinic mechanism designed to improve efficacy while reducing peripheral side effects and simplifying dosing. The company’s schizophrenia data showed a 210mg/3mg BID dose with a 4.5-point placebo-adjusted PANSS improvement, a 0.37 effect size, cognitive benefit, and only 7.1% discontinuations from TEAEs, suggesting a credible safety/tolerability profile versus competing therapies. Upstream, the ongoing VISTA trial in ADP and the potential for positive ADEPT readouts could validate the mechanism, while the reported $150M PIPE financing supports execution and lowers near-term funding risk.

Bears say

MapLight Therapeutics is viewed negatively because ML-007C-MA failed to hit the primary endpoint, while psychiatrists described its food-flexibility benefit as insufficient to offset weaker efficacy versus Cobenfy and questioned the adequacy of 5-week data for a chronic psychiatric disorder. The muscarinic market has shifted from an open field to a contested one, with Cobenfy setting the efficacy benchmark and compressing MapLight’s differentiation, while schizophrenia safety concerns and loss of tolerability advantage further limit adoption potential. As a result, the company faces lower modeled peak sales of about $400mn/$2bn in schizophrenia/ADP in 2037E, more judicious operating expenses, and a higher likelihood of additional financing needs.

MPLT has been analyzed by 11 analysts, with a consensus rating of Buy. 64% of analysts recommend a Strong Buy, 18% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MapLight Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

MPLT Analyst Forecast & Price Prediction

Get the latest MPLT stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MPLT

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MapLight Therapeutics Inc (MPLT) Forecast

Analysts have given MPLT a Buy based on their latest research and market trends.

According to 11 analysts, MPLT has a Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MapLight Therapeutics Inc (MPLT)


MPLT Analyst Forecast & Price Prediction

Get the latest MPLT stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MPLT

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover MPLT stock data and trends